How to Buy Mineralys Therapeutics Stock
Mineralys Therapeutics Inc
Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases.
Mineralys Therapeutics stock last closed at $30.87, down 0.06% from the previous day, and has increased 210.88% in one year. It has overperformed other stocks in the Biotechnology industry by 2.43 percentage points. Mineralys Therapeutics stock is currently +274.59% from its 52-week low of $8.24, and -35.22% from its 52-week high of $47.65.
As of Feb 2, 2026, there are 79.14M MLYS shares outstanding. The market value of MLYS is $2.44B. In the past 24 hours, 785,000 MLYS shares were traded.
How to Buy Mineralys Therapeutics Stock
Not sure how to invest in Mineralys Therapeutics stock? Here's how.
- Decide where to buy Mineralys Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Mineralys Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Select your payment method and add your info.
- Analyze Mineralys Therapeutics stock: The Mineralys Therapeutics ticker symbol is MLYS. Is Mineralys Therapeutics stock a good investment? Should you buy shares of MLYS? How do MLYS's underlying business fundamentals look? Do top analysts think Mineralys Therapeutics is a good buy? Why has MLYS's stock price moved recently? (Hint: Our stock research tools can help you decide if MLYS is a good stock to buy).
- Place your MLYS purchase: Decide if you will purchase MLYS shares at the current market price or use a limit order to buy MLYS shares at a given price.
- Get the latest news on your MLYS investment: Create a watchlist to the latest updates on your position in Mineralys Therapeutics stock.
Step 1: Decide where to buy Mineralys Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy MLYS stock.
Our recommended brokerage: eToro
Based on our experience, eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the right brokerage, you'll need to fill out some personal information so you are able to buy MLYS today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open your new brokerage account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've finished signing up on a good online stock trading app, you need to deposit funds:
Watch this video walkthrough to see the process of transferring funds into your brokerage account.
Step 4: Analyze Mineralys Therapeutics stock
After you have selected the best place to buy Mineralys Therapeutics stock, it's critical to analyze their stock before you buy, so you truly wrap your head around the risk and opportunity.
Mineralys Therapeutics quick stats
MLYS Due Diligence Checks
WallStreetZen was designed to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on MLYS's stock page.
Is MLYS stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge MLYS's fair value.
Using relative valuations measures:
- MLYS may be undervalued based on its P/B ratio of 4.24x, relative to Biotechnology industry P/B ratio of 5.49x
You can do more valuation analysis on MLYS's stock here.
MLYS Financial Summary
Positive Health Checks:
- MLYS has cash burn of 171371000. It has enough cash and short-term investments to cover this for at least one year.
- MLYS has a low debt to equity ratio of 0.04.
- There are more short-term assets than short-term liabilities on the MLYS balance sheet.
- MLYS has $593.63M in cash and short term investments. This is sufficient to cover its annual cash burn of $171.37M.
- There are more short-term assets than long-term liabilities on the MLYS balance sheet.
Do analysts think it's a good time to buy MLYS stock
Out of 6 Equities analysts who track MLYS, the consensus analyst rating on MLYS is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest MLYS Analyst Upgrades/Downgrades
Greg Harrison, a top 6% analyst from Bank of America maintains MLYS with a strong buy rating and raises their MLYS price target from $38.00 to $43.00, on Aug 28, 2025.
Bank of America's Greg Harrison raised their price target on Mineralys Therapeutics (NASDAQ: MLYS) by 13.2% from $38 to $43 on 2025/08/28. The analyst maintained their Strong Buy rating on the stock.
Mineralys Therapeutics reported its Q2 2025 earnings on 2025/08/12.
Harrison's price target hike was delivered in a post-print review of names in their SMid-Cap Biotech portfolio.
After adjusting for the quarter's results and taking into account management's guidance for a cash runway into 2027, the analyst said they made "modest" modifications to their Mineralys Therapeutics model.
You can dig deeper into what analysts are saying on the Mineralys Therapeutics stock forecast page.
MLYS Trading Indicators
Who is buying/selling MLYS?
Over the past year, insiders at MLYS have bought more shares than they have sold.
David Malcom Rodman, Chief Medical Officer of MLYS, was the latest MLYS insider to buy. They bought $6,423.04 worth of MLYS stock on Jan 20, 2026.
Dig into more about who owns MLYS stock here.
Does MLYS stock generate passive income?
No, Mineralys Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about MLYS
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your MLYS purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the best for newer investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given price, use a limit order.
Click the Open Trade button and eToro will place the order.
If you want additional help with investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your MLYS investment
Now that you own some shares in MLYS, you'll want to stay up-to-date on your investment.
Put MLYS on a watchlist to monitor your MLYS stock.
MLYS Feed
How to Buy Stock in Mineralys Therapeutics
To reiterate, here are the 6 steps for buying Mineralys Therapeutics stock:
- Decide where to buy Mineralys Therapeutics stock
- Open your brokerage account
- Put funds into your brokerage account
- Analyze Mineralys Therapeutics stock
- Place your MLYS purchase
- Get the latest news on your MLYS investment
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to get updates on your investment in Mineralys Therapeutics, add MLYS to your watchlist below.
More Content You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.